876379-22-5

Basic information

• Product Name: (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE
• Synonyms: (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE;Benzyl (3S)-3-[(tert-butoxycarbonyl)amino]piperidine-1-carboxylate;-1-Cbz-3-Boc-Aminopiperidine
• CAS NO: 876379-22-5
• Molecular Formula: C₁₈H₂₆N₂O₄
• Molecular Weight: 334.41
• Mol File: 876379-22-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 471.9±44.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.25±0.20(Predicted)
• CAS DataBase Reference: (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE(876379-22-5)
• EPA Substance Registry System: (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE(876379-22-5)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-37
• Hazardous Substances Data: 876379-22-5(Hazardous Substances Data)

Usage

General Description

"(S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE" is a chemical compound that falls into the category of protected amino acid derivatives. Both the CBZ (Carbobenzyloxy) and BOC (tert-butyloxycarbonyl) groups are used to protect the amine groups in amino acid and peptide synthesis. It has the specific role of a blocking agent that restricts particular reactions from taking place, thus helping chemists to synthesize the desired proteins or peptides accurately. Information regarding its specific uses, toxicity, and safety measures is generally provided on material safety data sheets by the suppliers. However, detailed information about this specific compound is not readily available in public resources, thus requiring further research specific to users' needs.

Upstream product

• 501-53-1 benzyl chloroformate 
• 216854-23-8 tert-butyl (S)-piperidin-3-yl-carbamate 

Downstream Products

• 1361323-51-4 tert-butyl (S)-1-((S)-3,3-dimethyl-1-((S)-1-(4-nitrophenethyl)piperidin-3-ylamino)-1-oxobutan-2-ylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-73-7 (S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)-N-((S)-1-(4-nitrophenethyl)piperidin-3-yl)butanamide 
• 1361323-52-5 tert-butyl (S)-1-((S)-3,3-dimethyl-1-oxo-1-((S)-1-(4-(trifluoromethyl)phenethyl)piperidin-3-ylamino)butan-2-ylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-74-8 (S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)-N-((S)-1-(4-(trifluoromethyl)phenethyl)piperidin-3-yl)butanamide 
• 876461-55-1 (S)-benzyl 3-aminopiperidine-1-carboxylate hydrochloride 
• 1361322-97-5 (S)-benzyl 3-((S)-2-(tert-butoxycarbonylamino)-2-cyclohexylacetamido)piperidine-1-carboxylate 
• 1361322-98-6 (S)-benzyl 3-((S)-2-amino-2-cyclohexylacetamido)piperidine-1-carboxylate hydrochloride 
• 1361322-99-7 (S)-benzyl 3-((S)-2-((S)-2-(tert-butoxycarbonyl(methyl)amino)propanamido)-2-cyclohexylacetamido)piperidine-1-carboxylate 
• 1361323-00-3 tert-butyl (S)-1-((S)-1-cyclohexyl-2-oxo-2-((S)-piperidin-3-ylamino)ethylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-49-7 (S)-N-((S)-2-((S)-1-benzylpiperidin-3-ylamino)-1-cyclohexyl-2-oxoethyl)-2-(methylamino)propanamide 
• 1361322-50-0 (S)-N-((S)-1-cyclohexyl-2-oxo-2-((S)-1-(3-phenylpropyl)piperidin-3-ylamino)ethyl)-2-(methylamino)propanamide 
• 1361323-01-4 tert-butyl (S)-1-((S)-2-((S)-1-benzoylpiperidin-3-ylamino)-1-cyclohexyl-2-oxoethylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361323-02-5 tert-butyl (S)-1-((S)-1-cyclohexyl-2-oxo-2-((S)-1-(2-phenylacetyl)piperidin-3-ylamino)ethylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-51-1 (S)-N-((S)-2-((S)-1-benzoylpiperidin-3-ylamino)-1-cyclohexyl-2-oxoethyl)-2-(methylamino)propanamide 

Relevant articles and documents

Discovery of DS34942424: An orally potent analgesic without mu opioid receptor agonist activity

We identified (5′S)-10′-fluoro-6′-methyl-5′,6′-dihydro-3′H-spiro[cyclopropane-1,4′-[2,6]diaza[2,5]methano[2,6]benzodiazonin]-7′(1′H)-one, 22b (DS34942424) with a unique and original bicyclic skeleton. 22b showed an orally potent analgesic in the acetic ac

QUINAZOLINEDIONE DERIVATIVE

The present invention relates to quinazolinedione derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

HETEROCYCLIC TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.